Dare Bioscience (NASDAQ:DARE)’s share price shot up 5.5% during mid-day trading on Thursday . The company traded as high as $1.22 and last traded at $1.16. 760,900 shares traded hands during mid-day trading, a decline of 19% from the average session volume of 937,513 shares. The stock had previously closed at $1.10.
A number of brokerages recently issued reports on DARE. Roth Capital began coverage on shares of Dare Bioscience in a research report on Wednesday. They issued a “buy” rating and a $6.00 target price for the company. ValuEngine upgraded shares of Dare Bioscience from a “sell” rating to a “hold” rating in a research report on Wednesday, May 2nd.
Dare Bioscience (NASDAQ:DARE) last announced its earnings results on Monday, April 2nd. The biotechnology company reported ($0.49) earnings per share (EPS) for the quarter.
Dare Bioscience Company Profile
Daré Bioscience, Inc, a clinical-stage biopharmaceutical company, focuses on developing and marketing women's reproductive health products in the United States. The company intends to develop therapies in the areas of contraception, vaginal health, sexual health, and fertility. Its product candidates include Ovaprene, a non-hormonal monthly contraceptive; and SST-6007, a topical sildenafil cream for female sexual arousal disorder.
Receive News & Ratings for Dare Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dare Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.